nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefotetan—ALB—Fluorouracil—urinary bladder cancer	0.284	0.645	CbGbCtD
Cefotetan—ALB—Methotrexate—urinary bladder cancer	0.156	0.355	CbGbCtD
Cefotetan—Superinfection—Fluorouracil—urinary bladder cancer	0.0234	0.0417	CcSEcCtD
Cefotetan—Nephropathy toxic—Mitomycin—urinary bladder cancer	0.0222	0.0397	CcSEcCtD
Cefotetan—Phlebitis—Carboplatin—urinary bladder cancer	0.0145	0.0258	CcSEcCtD
Cefotetan—Nephropathy toxic—Gemcitabine—urinary bladder cancer	0.0094	0.0168	CcSEcCtD
Cefotetan—Nephropathy toxic—Cisplatin—urinary bladder cancer	0.00876	0.0156	CcSEcCtD
Cefotetan—Thrombocytosis—Gemcitabine—urinary bladder cancer	0.00868	0.0155	CcSEcCtD
Cefotetan—Nephropathy toxic—Etoposide—urinary bladder cancer	0.00803	0.0143	CcSEcCtD
Cefotetan—Pancytopenia—Mitomycin—urinary bladder cancer	0.0076	0.0136	CcSEcCtD
Cefotetan—Discomfort—Valrubicin—urinary bladder cancer	0.00681	0.0122	CcSEcCtD
Cefotetan—Blood bilirubin increased—Thiotepa—urinary bladder cancer	0.00679	0.0121	CcSEcCtD
Cefotetan—Prothrombin level increased—Epirubicin—urinary bladder cancer	0.0063	0.0112	CcSEcCtD
Cefotetan—Colitis—Thiotepa—urinary bladder cancer	0.00616	0.011	CcSEcCtD
Cefotetan—Prothrombin level increased—Doxorubicin—urinary bladder cancer	0.00583	0.0104	CcSEcCtD
Cefotetan—Blood bilirubin increased—Gemcitabine—urinary bladder cancer	0.00571	0.0102	CcSEcCtD
Cefotetan—Gastrointestinal pain—Valrubicin—urinary bladder cancer	0.0054	0.00965	CcSEcCtD
Cefotetan—Body temperature increased—Valrubicin—urinary bladder cancer	0.00522	0.00933	CcSEcCtD
Cefotetan—Abdominal pain—Valrubicin—urinary bladder cancer	0.00522	0.00933	CcSEcCtD
Cefotetan—Vaginal moniliasis—Epirubicin—urinary bladder cancer	0.00512	0.00914	CcSEcCtD
Cefotetan—Leukopenia—Mitomycin—urinary bladder cancer	0.00499	0.00892	CcSEcCtD
Cefotetan—Vulvovaginal candidiasis—Epirubicin—urinary bladder cancer	0.00491	0.00878	CcSEcCtD
Cefotetan—Body temperature increased—Carboplatin—urinary bladder cancer	0.00484	0.00864	CcSEcCtD
Cefotetan—Vaginal moniliasis—Doxorubicin—urinary bladder cancer	0.00474	0.00846	CcSEcCtD
Cefotetan—Vulvovaginal mycotic infection—Epirubicin—urinary bladder cancer	0.00473	0.00844	CcSEcCtD
Cefotetan—Discomfort—Mitomycin—urinary bladder cancer	0.00469	0.00838	CcSEcCtD
Cefotetan—Pruritus—Valrubicin—urinary bladder cancer	0.00468	0.00835	CcSEcCtD
Cefotetan—Vulvovaginal candidiasis—Doxorubicin—urinary bladder cancer	0.00455	0.00812	CcSEcCtD
Cefotetan—Diarrhoea—Valrubicin—urinary bladder cancer	0.00452	0.00807	CcSEcCtD
Cefotetan—Hepatic function abnormal—Gemcitabine—urinary bladder cancer	0.00448	0.00801	CcSEcCtD
Cefotetan—Thrombocytopenia—Mitomycin—urinary bladder cancer	0.00446	0.00796	CcSEcCtD
Cefotetan—Vulvovaginal mycotic infection—Doxorubicin—urinary bladder cancer	0.00437	0.00781	CcSEcCtD
Cefotetan—Phlebitis—Cisplatin—urinary bladder cancer	0.00424	0.00757	CcSEcCtD
Cefotetan—Vomiting—Valrubicin—urinary bladder cancer	0.0042	0.0075	CcSEcCtD
Cefotetan—Rash—Valrubicin—urinary bladder cancer	0.00417	0.00744	CcSEcCtD
Cefotetan—Dermatitis—Valrubicin—urinary bladder cancer	0.00416	0.00743	CcSEcCtD
Cefotetan—Thrombocytosis—Epirubicin—urinary bladder cancer	0.00416	0.00742	CcSEcCtD
Cefotetan—Haemolytic anaemia—Cisplatin—urinary bladder cancer	0.00405	0.00722	CcSEcCtD
Cefotetan—Nausea—Valrubicin—urinary bladder cancer	0.00393	0.00701	CcSEcCtD
Cefotetan—Phlebitis—Etoposide—urinary bladder cancer	0.00388	0.00694	CcSEcCtD
Cefotetan—Thrombocytosis—Doxorubicin—urinary bladder cancer	0.00385	0.00687	CcSEcCtD
Cefotetan—Pancytopenia—Thiotepa—urinary bladder cancer	0.00382	0.00683	CcSEcCtD
Cefotetan—Body temperature increased—Mitomycin—urinary bladder cancer	0.0036	0.00643	CcSEcCtD
Cefotetan—Toxic epidermal necrolysis—Gemcitabine—urinary bladder cancer	0.00353	0.0063	CcSEcCtD
Cefotetan—Agranulocytosis—Thiotepa—urinary bladder cancer	0.00335	0.00598	CcSEcCtD
Cefotetan—Eosinophilia—Fluorouracil—urinary bladder cancer	0.0033	0.00589	CcSEcCtD
Cefotetan—Haemoglobin—Thiotepa—urinary bladder cancer	0.00324	0.00578	CcSEcCtD
Cefotetan—Haemorrhage—Thiotepa—urinary bladder cancer	0.00322	0.00575	CcSEcCtD
Cefotetan—Pancytopenia—Gemcitabine—urinary bladder cancer	0.00322	0.00574	CcSEcCtD
Cefotetan—Neutropenia—Gemcitabine—urinary bladder cancer	0.00317	0.00566	CcSEcCtD
Cefotetan—Pancytopenia—Fluorouracil—urinary bladder cancer	0.00316	0.00565	CcSEcCtD
Cefotetan—Diarrhoea—Mitomycin—urinary bladder cancer	0.00312	0.00556	CcSEcCtD
Cefotetan—Toxic epidermal necrolysis—Etoposide—urinary bladder cancer	0.00301	0.00538	CcSEcCtD
Cefotetan—Pancytopenia—Cisplatin—urinary bladder cancer	0.003	0.00535	CcSEcCtD
Cefotetan—Stevens-Johnson syndrome—Gemcitabine—urinary bladder cancer	0.00299	0.00535	CcSEcCtD
Cefotetan—Vomiting—Mitomycin—urinary bladder cancer	0.00289	0.00517	CcSEcCtD
Cefotetan—Rash—Mitomycin—urinary bladder cancer	0.00287	0.00513	CcSEcCtD
Cefotetan—Dermatitis—Mitomycin—urinary bladder cancer	0.00287	0.00512	CcSEcCtD
Cefotetan—Agranulocytosis—Gemcitabine—urinary bladder cancer	0.00282	0.00503	CcSEcCtD
Cefotetan—Agranulocytosis—Fluorouracil—urinary bladder cancer	0.00277	0.00495	CcSEcCtD
Cefotetan—Vaginal inflammation—Methotrexate—urinary bladder cancer	0.00276	0.00493	CcSEcCtD
Cefotetan—Pancytopenia—Etoposide—urinary bladder cancer	0.00275	0.0049	CcSEcCtD
Cefotetan—Blood bilirubin increased—Epirubicin—urinary bladder cancer	0.00273	0.00488	CcSEcCtD
Cefotetan—Haemoglobin—Gemcitabine—urinary bladder cancer	0.00272	0.00487	CcSEcCtD
Cefotetan—Haemorrhage—Gemcitabine—urinary bladder cancer	0.00271	0.00484	CcSEcCtD
Cefotetan—Neutropenia—Etoposide—urinary bladder cancer	0.0027	0.00483	CcSEcCtD
Cefotetan—Nausea—Mitomycin—urinary bladder cancer	0.0027	0.00483	CcSEcCtD
Cefotetan—Haemoglobin—Fluorouracil—urinary bladder cancer	0.00268	0.00478	CcSEcCtD
Cefotetan—Haemorrhage—Fluorouracil—urinary bladder cancer	0.00267	0.00476	CcSEcCtD
Cefotetan—Vaginal infection—Methotrexate—urinary bladder cancer	0.00261	0.00465	CcSEcCtD
Cefotetan—Aplastic anaemia—Methotrexate—urinary bladder cancer	0.00259	0.00463	CcSEcCtD
Cefotetan—Vaginal inflammation—Epirubicin—urinary bladder cancer	0.00258	0.00461	CcSEcCtD
Cefotetan—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.00256	0.00458	CcSEcCtD
Cefotetan—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.00256	0.00457	CcSEcCtD
Cefotetan—Blood bilirubin increased—Doxorubicin—urinary bladder cancer	0.00253	0.00451	CcSEcCtD
Cefotetan—Leukopenia—Thiotepa—urinary bladder cancer	0.00251	0.00448	CcSEcCtD
Cefotetan—Colitis—Epirubicin—urinary bladder cancer	0.00248	0.00443	CcSEcCtD
Cefotetan—Vaginal infection—Epirubicin—urinary bladder cancer	0.00244	0.00436	CcSEcCtD
Cefotetan—Convulsion—Thiotepa—urinary bladder cancer	0.00243	0.00434	CcSEcCtD
Cefotetan—Aplastic anaemia—Epirubicin—urinary bladder cancer	0.00243	0.00433	CcSEcCtD
Cefotetan—Agranulocytosis—Etoposide—urinary bladder cancer	0.00241	0.0043	CcSEcCtD
Cefotetan—Vaginal inflammation—Doxorubicin—urinary bladder cancer	0.00239	0.00427	CcSEcCtD
Cefotetan—Colitis—Doxorubicin—urinary bladder cancer	0.0023	0.0041	CcSEcCtD
Cefotetan—Vaginal infection—Doxorubicin—urinary bladder cancer	0.00226	0.00403	CcSEcCtD
Cefotetan—Aplastic anaemia—Doxorubicin—urinary bladder cancer	0.00224	0.00401	CcSEcCtD
Cefotetan—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.00224	0.004	CcSEcCtD
Cefotetan—Erythema multiforme—Etoposide—urinary bladder cancer	0.00219	0.00391	CcSEcCtD
Cefotetan—Phlebitis—Epirubicin—urinary bladder cancer	0.00218	0.00389	CcSEcCtD
Cefotetan—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.00215	0.00383	CcSEcCtD
Cefotetan—Leukopenia—Gemcitabine—urinary bladder cancer	0.00211	0.00377	CcSEcCtD
Cefotetan—Leukopenia—Fluorouracil—urinary bladder cancer	0.00208	0.00371	CcSEcCtD
Cefotetan—Phlebitis—Doxorubicin—urinary bladder cancer	0.00201	0.0036	CcSEcCtD
Cefotetan—Convulsion—Fluorouracil—urinary bladder cancer	0.00201	0.00359	CcSEcCtD
Cefotetan—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.00199	0.00355	CcSEcCtD
Cefotetan—Discomfort—Gemcitabine—urinary bladder cancer	0.00199	0.00354	CcSEcCtD
Cefotetan—Leukopenia—Cisplatin—urinary bladder cancer	0.00197	0.00352	CcSEcCtD
Cefotetan—Discomfort—Fluorouracil—urinary bladder cancer	0.00195	0.00349	CcSEcCtD
Cefotetan—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00193	0.00344	CcSEcCtD
Cefotetan—Convulsion—Cisplatin—urinary bladder cancer	0.00191	0.0034	CcSEcCtD
Cefotetan—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00189	0.00338	CcSEcCtD
Cefotetan—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.00189	0.00337	CcSEcCtD
Cefotetan—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00187	0.00334	CcSEcCtD
Cefotetan—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00185	0.00331	CcSEcCtD
Cefotetan—Discomfort—Cisplatin—urinary bladder cancer	0.00185	0.0033	CcSEcCtD
Cefotetan—Urticaria—Thiotepa—urinary bladder cancer	0.00182	0.00325	CcSEcCtD
Cefotetan—Abdominal pain—Thiotepa—urinary bladder cancer	0.00181	0.00323	CcSEcCtD
Cefotetan—Body temperature increased—Thiotepa—urinary bladder cancer	0.00181	0.00323	CcSEcCtD
Cefotetan—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.0018	0.00322	CcSEcCtD
Cefotetan—Leukopenia—Etoposide—urinary bladder cancer	0.0018	0.00322	CcSEcCtD
Cefotetan—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.0018	0.00321	CcSEcCtD
Cefotetan—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.00176	0.00314	CcSEcCtD
Cefotetan—Convulsion—Etoposide—urinary bladder cancer	0.00175	0.00312	CcSEcCtD
Cefotetan—Eosinophilia—Methotrexate—urinary bladder cancer	0.00172	0.00306	CcSEcCtD
Cefotetan—Discomfort—Etoposide—urinary bladder cancer	0.0017	0.00303	CcSEcCtD
Cefotetan—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.00169	0.00302	CcSEcCtD
Cefotetan—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00169	0.00301	CcSEcCtD
Cefotetan—Pancytopenia—Methotrexate—urinary bladder cancer	0.00165	0.00294	CcSEcCtD
Cefotetan—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00164	0.00294	CcSEcCtD
Cefotetan—Neutropenia—Methotrexate—urinary bladder cancer	0.00162	0.00289	CcSEcCtD
Cefotetan—Pruritus—Thiotepa—urinary bladder cancer	0.00162	0.00289	CcSEcCtD
Cefotetan—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00161	0.00288	CcSEcCtD
Cefotetan—Eosinophilia—Epirubicin—urinary bladder cancer	0.00161	0.00287	CcSEcCtD
Cefotetan—Diarrhoea—Thiotepa—urinary bladder cancer	0.00157	0.0028	CcSEcCtD
Cefotetan—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.00156	0.00279	CcSEcCtD
Cefotetan—Pancytopenia—Epirubicin—urinary bladder cancer	0.00154	0.00275	CcSEcCtD
Cefotetan—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.00153	0.00273	CcSEcCtD
Cefotetan—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00152	0.00272	CcSEcCtD
Cefotetan—Neutropenia—Epirubicin—urinary bladder cancer	0.00152	0.00271	CcSEcCtD
Cefotetan—Urticaria—Fluorouracil—urinary bladder cancer	0.0015	0.00269	CcSEcCtD
Cefotetan—Body temperature increased—Fluorouracil—urinary bladder cancer	0.0015	0.00267	CcSEcCtD
Cefotetan—Eosinophilia—Doxorubicin—urinary bladder cancer	0.00149	0.00265	CcSEcCtD
Cefotetan—Vomiting—Thiotepa—urinary bladder cancer	0.00146	0.0026	CcSEcCtD
Cefotetan—Rash—Thiotepa—urinary bladder cancer	0.00144	0.00258	CcSEcCtD
Cefotetan—Dermatitis—Thiotepa—urinary bladder cancer	0.00144	0.00258	CcSEcCtD
Cefotetan—Agranulocytosis—Methotrexate—urinary bladder cancer	0.00144	0.00257	CcSEcCtD
Cefotetan—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.00143	0.00256	CcSEcCtD
Cefotetan—Pancytopenia—Doxorubicin—urinary bladder cancer	0.00142	0.00254	CcSEcCtD
Cefotetan—Body temperature increased—Cisplatin—urinary bladder cancer	0.00142	0.00253	CcSEcCtD
Cefotetan—Neutropenia—Doxorubicin—urinary bladder cancer	0.0014	0.0025	CcSEcCtD
Cefotetan—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.0014	0.00249	CcSEcCtD
Cefotetan—Haemoglobin—Methotrexate—urinary bladder cancer	0.00139	0.00249	CcSEcCtD
Cefotetan—Haemorrhage—Methotrexate—urinary bladder cancer	0.00139	0.00248	CcSEcCtD
Cefotetan—Pruritus—Gemcitabine—urinary bladder cancer	0.00136	0.00243	CcSEcCtD
Cefotetan—Nausea—Thiotepa—urinary bladder cancer	0.00136	0.00243	CcSEcCtD
Cefotetan—Agranulocytosis—Epirubicin—urinary bladder cancer	0.00135	0.00241	CcSEcCtD
Cefotetan—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00134	0.0024	CcSEcCtD
Cefotetan—Pruritus—Fluorouracil—urinary bladder cancer	0.00134	0.00239	CcSEcCtD
Cefotetan—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00133	0.00237	CcSEcCtD
Cefotetan—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00132	0.00236	CcSEcCtD
Cefotetan—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00132	0.00235	CcSEcCtD
Cefotetan—Erythema multiforme—Methotrexate—urinary bladder cancer	0.00131	0.00234	CcSEcCtD
Cefotetan—Urticaria—Etoposide—urinary bladder cancer	0.00131	0.00233	CcSEcCtD
Cefotetan—Haemoglobin—Epirubicin—urinary bladder cancer	0.0013	0.00233	CcSEcCtD
Cefotetan—Abdominal pain—Etoposide—urinary bladder cancer	0.0013	0.00232	CcSEcCtD
Cefotetan—Body temperature increased—Etoposide—urinary bladder cancer	0.0013	0.00232	CcSEcCtD
Cefotetan—Haemorrhage—Epirubicin—urinary bladder cancer	0.0013	0.00232	CcSEcCtD
Cefotetan—Diarrhoea—Fluorouracil—urinary bladder cancer	0.0013	0.00231	CcSEcCtD
Cefotetan—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.00125	0.00223	CcSEcCtD
Cefotetan—Diarrhoea—Cisplatin—urinary bladder cancer	0.00123	0.00219	CcSEcCtD
Cefotetan—Erythema multiforme—Epirubicin—urinary bladder cancer	0.00123	0.00219	CcSEcCtD
Cefotetan—Vomiting—Gemcitabine—urinary bladder cancer	0.00122	0.00219	CcSEcCtD
Cefotetan—Rash—Gemcitabine—urinary bladder cancer	0.00121	0.00217	CcSEcCtD
Cefotetan—Dermatitis—Gemcitabine—urinary bladder cancer	0.00121	0.00217	CcSEcCtD
Cefotetan—Hypersensitivity—Etoposide—urinary bladder cancer	0.00121	0.00216	CcSEcCtD
Cefotetan—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00121	0.00215	CcSEcCtD
Cefotetan—Vomiting—Fluorouracil—urinary bladder cancer	0.0012	0.00215	CcSEcCtD
Cefotetan—Haemorrhage—Doxorubicin—urinary bladder cancer	0.0012	0.00214	CcSEcCtD
Cefotetan—Rash—Fluorouracil—urinary bladder cancer	0.00119	0.00213	CcSEcCtD
Cefotetan—Dermatitis—Fluorouracil—urinary bladder cancer	0.00119	0.00213	CcSEcCtD
Cefotetan—Pruritus—Etoposide—urinary bladder cancer	0.00116	0.00208	CcSEcCtD
Cefotetan—Nausea—Gemcitabine—urinary bladder cancer	0.00114	0.00204	CcSEcCtD
Cefotetan—Vomiting—Cisplatin—urinary bladder cancer	0.00114	0.00204	CcSEcCtD
Cefotetan—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.00114	0.00203	CcSEcCtD
Cefotetan—Rash—Cisplatin—urinary bladder cancer	0.00113	0.00202	CcSEcCtD
Cefotetan—Dermatitis—Cisplatin—urinary bladder cancer	0.00113	0.00202	CcSEcCtD
Cefotetan—Diarrhoea—Etoposide—urinary bladder cancer	0.00113	0.00201	CcSEcCtD
Cefotetan—Nausea—Fluorouracil—urinary bladder cancer	0.00112	0.00201	CcSEcCtD
Cefotetan—Leukopenia—Methotrexate—urinary bladder cancer	0.00108	0.00193	CcSEcCtD
Cefotetan—Nausea—Cisplatin—urinary bladder cancer	0.00107	0.0019	CcSEcCtD
Cefotetan—Convulsion—Methotrexate—urinary bladder cancer	0.00105	0.00187	CcSEcCtD
Cefotetan—Vomiting—Etoposide—urinary bladder cancer	0.00105	0.00187	CcSEcCtD
Cefotetan—Rash—Etoposide—urinary bladder cancer	0.00104	0.00185	CcSEcCtD
Cefotetan—Dermatitis—Etoposide—urinary bladder cancer	0.00104	0.00185	CcSEcCtD
Cefotetan—Discomfort—Methotrexate—urinary bladder cancer	0.00102	0.00181	CcSEcCtD
Cefotetan—Leukopenia—Epirubicin—urinary bladder cancer	0.00101	0.00181	CcSEcCtD
Cefotetan—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000985	0.00176	CcSEcCtD
Cefotetan—Convulsion—Epirubicin—urinary bladder cancer	0.000979	0.00175	CcSEcCtD
Cefotetan—Nausea—Etoposide—urinary bladder cancer	0.000977	0.00174	CcSEcCtD
Cefotetan—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000965	0.00172	CcSEcCtD
Cefotetan—Discomfort—Epirubicin—urinary bladder cancer	0.00095	0.0017	CcSEcCtD
Cefotetan—Leukopenia—Doxorubicin—urinary bladder cancer	0.000936	0.00167	CcSEcCtD
Cefotetan—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000922	0.00165	CcSEcCtD
Cefotetan—Convulsion—Doxorubicin—urinary bladder cancer	0.000906	0.00162	CcSEcCtD
Cefotetan—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000903	0.00161	CcSEcCtD
Cefotetan—Discomfort—Doxorubicin—urinary bladder cancer	0.000879	0.00157	CcSEcCtD
Cefotetan—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000853	0.00152	CcSEcCtD
Cefotetan—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000835	0.00149	CcSEcCtD
Cefotetan—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000806	0.00144	CcSEcCtD
Cefotetan—Urticaria—Methotrexate—urinary bladder cancer	0.000783	0.0014	CcSEcCtD
Cefotetan—Abdominal pain—Methotrexate—urinary bladder cancer	0.000779	0.00139	CcSEcCtD
Cefotetan—Body temperature increased—Methotrexate—urinary bladder cancer	0.000779	0.00139	CcSEcCtD
Cefotetan—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000754	0.00135	CcSEcCtD
Cefotetan—Urticaria—Epirubicin—urinary bladder cancer	0.000732	0.00131	CcSEcCtD
Cefotetan—Abdominal pain—Epirubicin—urinary bladder cancer	0.000729	0.0013	CcSEcCtD
Cefotetan—Body temperature increased—Epirubicin—urinary bladder cancer	0.000729	0.0013	CcSEcCtD
Cefotetan—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000726	0.0013	CcSEcCtD
Cefotetan—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000698	0.00125	CcSEcCtD
Cefotetan—Pruritus—Methotrexate—urinary bladder cancer	0.000697	0.00124	CcSEcCtD
Cefotetan—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000679	0.00121	CcSEcCtD
Cefotetan—Urticaria—Doxorubicin—urinary bladder cancer	0.000678	0.00121	CcSEcCtD
Cefotetan—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000674	0.0012	CcSEcCtD
Cefotetan—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000674	0.0012	CcSEcCtD
Cefotetan—Diarrhoea—Methotrexate—urinary bladder cancer	0.000674	0.0012	CcSEcCtD
Cefotetan—Pruritus—Epirubicin—urinary bladder cancer	0.000652	0.00116	CcSEcCtD
Cefotetan—Diarrhoea—Epirubicin—urinary bladder cancer	0.000631	0.00113	CcSEcCtD
Cefotetan—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000629	0.00112	CcSEcCtD
Cefotetan—Vomiting—Methotrexate—urinary bladder cancer	0.000626	0.00112	CcSEcCtD
Cefotetan—Rash—Methotrexate—urinary bladder cancer	0.000621	0.00111	CcSEcCtD
Cefotetan—Dermatitis—Methotrexate—urinary bladder cancer	0.000621	0.00111	CcSEcCtD
Cefotetan—Pruritus—Doxorubicin—urinary bladder cancer	0.000604	0.00108	CcSEcCtD
Cefotetan—Vomiting—Epirubicin—urinary bladder cancer	0.000586	0.00105	CcSEcCtD
Cefotetan—Nausea—Methotrexate—urinary bladder cancer	0.000585	0.00104	CcSEcCtD
Cefotetan—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000584	0.00104	CcSEcCtD
Cefotetan—Rash—Epirubicin—urinary bladder cancer	0.000581	0.00104	CcSEcCtD
Cefotetan—Dermatitis—Epirubicin—urinary bladder cancer	0.000581	0.00104	CcSEcCtD
Cefotetan—Nausea—Epirubicin—urinary bladder cancer	0.000548	0.000978	CcSEcCtD
Cefotetan—Vomiting—Doxorubicin—urinary bladder cancer	0.000542	0.000968	CcSEcCtD
Cefotetan—Rash—Doxorubicin—urinary bladder cancer	0.000538	0.00096	CcSEcCtD
Cefotetan—Dermatitis—Doxorubicin—urinary bladder cancer	0.000537	0.00096	CcSEcCtD
Cefotetan—Nausea—Doxorubicin—urinary bladder cancer	0.000507	0.000905	CcSEcCtD
